NZ757752B2 - Inhaler with synthetic jetting - Google Patents

Abstract

dry powder inhaler consisting of a reusable base unit and a disposable drug package is disclosed. The reusable portion may house a transducer, a controller, battery and user interface. The disposable portion may house a dose pellet in a sealed dose chamber that includes an integrated mouthpiece. A user may couple the disposable portion to the reusable portion of the inhaler. The inhaler may sense the user's breathe and synchronize delivery of the pharmaceutical or drug to the user. user may couple the disposable portion to the reusable portion of the inhaler. The inhaler may sense the user's breathe and synchronize delivery of the pharmaceutical or drug to the user.

Description

INHALER WITH TIC G REFERENCE TO PRIOR APPLICATIONS This application claims priority to US. Provisional Patent Application No. 62/511,778, ?led May 26, 2017, which is hereby expressly incorporated by reference in its entirety.

FIELD The embodiments relate generally to the ?eld of delivery of pharmaceuticals and drugs. Particular utility may be found in the delivery of a pharmaceutical or drug to a patient utilizing a portable le base unit and a disposable drug package and will be described in tion with such utility, although other utilities are contemplated, BACKGROUND Certain diseases of the respiratory tract are known to respond to treatment by the direct application of therapeutic agents. As these agents are most readily available in dry powdered form, their application is most conveniently accomplished by inhaling the powdered material through the nose or mouth. This powdered form results in the better utilization of the medication in that the drug is deposited exactly at the site desired and where its action may be ed, hence, very minute doses of the drug are often equally as efficacious as larger doses administered by other means, with a consequent marked reduction in the incidence of undesired side effects and tion cost. Alternatively, the drug in powdered form may be used for treatment of diseases other than those of the respiratory system. When the drug is deposited on the very large surface areas of the lungs, it may be very rapidly absorbed into the blood stream; hence, this method of application may take the place of administration by injection, tablet, or other conventional means.

Existing dry powder inhalers (DPIs) usually have a means for introducing a drug (active drug plus carrier) into a high velocity air-stream. The high velocity air-stream is used as the primary mechanism for breaking up the cluster of micronized particles or separating the drug particles from the carrier. These ng devices present several ms and possess several disadvantages. First, conventional DPIs, generally being passive devices, require the user to forcefully exhale then deeply inhale for optimal drug delivery. Such a disadvantage impacts more severely affected patients by requiring them to n dif?cult breathing patterns through an inhaler with a large amount of ance. A need exists for a device which enables the user to breathe normally during dosing. r, conventional DPIs are highly sophisticated devices which are suited for consumers in highly developed nations. There is a market need for a ?ed design that is more cost competitive for developing nations. Such a device may address many of the challenges of conventional DPIs such as eliminating the complicated dose e mechanisms, fying the human factors design, and reducing the t cost. For example, many conventional multi-dose inhalers utilize blister strips or a series of individual blisters which require complicated mechanisms for reliable dose advance. Moreover, a sophisticated multi—dose inhaler may include an electric motor coupled to software for controlling the dose advance within a cartridge. These multi-dose inhalers may also provide wireless tivity and a LCD user interface. Storage for the le dosages also enlarges the size of the disposable drug cartridge. All these factors result in an inhaler that may be too expensive for ping markets thus denying the unique drug delivery technology to those who need it most.

SUMMARY Embodiments described herein relate to s, apparatuses, and/or systems for delivering a dose of a pharmaceutical or drug through an inhaler. In certain embodiments, the inhaler may comprise a reusable base unit and a disposable drug package. In some embodiments, the reusable portion may house a transducer, a controller, battery and user ace. In other ments, the disposable portion may house a dose of medicament in a sealed dose chamber that includes an integrated mouthpiece. In one embodiment, during operation, a user may insert the disposable portion onto the reusable portion of the inhaler.

Next, the user may remove a seal attached to the disposable portion to expose a pharmaceutical or drug located within the dose chamber. The user may then bring the mouthpiece to their lips and start to breathe normally. During this time, the inhaler may sense the user’s breathe and synchronize delivery of the pharmaceutical or drug to the user utilizing synthetic jetting. During use, an indicator, such as the light, at the distal end of the reusable portion may illuminate to indicate proper function of the inhaler.

In another embodiment, the ucer of the reusable n of the inhaler may create an acoustic wave that aerosolizes the dry powder pharmaceutical or drug located in the dosing chamber via synthetic jetting. The aerosolized medication may be emitted into the air?ow ?ow t and is entrained into the inhaled air via the mouthpiece and thereby into the user. Inhalation may be actively detected by the inhaler to synchronize delivery of the pharmaceutical or drug to the user. The pharmaceutical or drug may be prepared by compressing the micronized dry powder into a single pre-metered dose pellet which is packaged into individual blister packs. In one embodiment, a single pre-metered dose pellet may include a container closure system and an acoustic chamber for tic g.

In accordance with one embodiment, a dry powder inhaler is provided. The dry powder inhaler includes a ?rst portion including a dry powder medicament, a dosing chamber con?gured to receive the medicament, and a mouthpiece con?gured to deliver the medicament in aerosolized form to the user. The dry powder inhaler also includes a second portion including a transducer con?gured to aerosolize the medicament when the transducer is activated and a controller con?gured to activate the transducer in response to an activation event. The ?rst portion and the second portion may be coupled together at a connection point.

In some embodiments, the ?rst n and the second portion e outer tubular housings extending in a longitudinal direction. In some embodiments, the inhaler is about 5-15 millimeters in er and about 80-150 millimeters in length when the ?rst portion and the second n are coupled together. In some embodiments, the ?rst portion is disposable and the second portion is reusable.

In ance with another embodiment, a method for delivering a dose of a drug with an inhaler is provided. The method includes coupling a ?rst and second portion of the inhaler, providing a dry powder medicament located in the ?rst portion of the inhaler, and aerosolizing the dry powder medicament via a transducer in the second portion of the inhaler.

The transducer may be activated in response to an activation event via controller in the second portion of the inhaler. The method further includes receiving an aerosolized form of the dry powder in a dosing chamber within the ?rst portion of the inhaler and delivering the aerosolized dry powder through a iece of the ?rst portion of the inhaler. In some embodiments, the ?rst portion and the second portion e outer tubular housings ing in a udinal direction. In some embodiments, the inhaler is about 5-15 millimeters in er and about 80-150 millimeters in length when the ?rst n and the second portion are coupled together. In some embodiments, the ?rst portion is disposable and the second portion is reusable.

These methods, apparatuses, and/or systems provide signi?cant ages. First, the inhaler provides a simpli?ed design eliminating the complicated dose advance mechanisms which may be more cost competitive in the market. Further, the synthetic g provided by the inhaler s the user to breathe normally during dosing as compared to conventional passive rs which require the user to forcefully exhale then deeply inhale for optimal drug delivery.

Various other aspects, features, and advantages will be apparent through the ed description and the drawings attached . It is also to be tood that both the foregoing general description and the following detailed description are exemplary and not restrictive of the scope of the embodiments. As used in the specification and in the claims, the singular forms of (6 33 (C , an", and "the" include plural referents unless the context clearly dictates ise. In addition, as used in the speci?cation and the , the term "or" means "and/or" unless the context clearly dictates otherwise.

BRIEF DESCRIPTION OF THE DRAWINGS FIGS. lA—C show a perspective view of an inhaler, in accordance with one or more embodiments.

FIGS. 2A and B show a perspective view of the ng and initiation of operation of an inhaler, in accordance with one or more ments.

FIGS. 3A and B show a zoomed perspective View of an inhaler, in accordance with one or more embodiments. shows a ?owchart of a method of delivering a dose of a drug with an inhaler, in accordance with one or more embodiments.

DETAILED DESCRIPTION In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the embodiments. It will be appreciated, however, by those having skill in the art that the ments may be practiced without these specific details or with an equivalent arrangement. In other instances, well-known structures and devices are shown in block diagram form in order to avoid unnecessarily obscuring the embodiments of the invention.

The present embodiments relate to a device for administering medicament as a dry powder for inhalation by a user. Some embodiments of the device may be classified as a dry powder inhaler (DPI). Some embodiments of the device may also be classified as a dry powder nebulizer (as opposed to a liquid nebulizer), particularly when tidal breathing is used to deliver dry powder medicament over one or more inhalations. The device may be referred to herein interchangeably as a "device" or an "inhaler," both of which refer to a device for stering medicament as a dry powder for inhalation by a subject, and most preferably when tidal breathing is used "Tidal ing" preferably refers to inhalation and exhalation during normal breathing at rest, as opposed to forceful breathing.

Structure of an tion Device FIGS. lA-C show an inhaler 100 con?gured to receive a user’s inhale through the mouthpiece of the device, preferably via tidal breathing, and r a dose of medicament over one or more consecutive inhalations. As shown in FIGS. lA-C, inhaler 100 may include a le portion 102 and a disposable portion 104, which may be coupled together at a connection point 106 or by other convenience such as a snug-fit, detent, clamp and/or clasp.

In one embodiment, the reusable portion 102 may include an outer tubular housing 108 extending in a longitudinal direction for housing a transducer 110, controller 112, battery 114 and user interface 116. The disposable portion 104 may also include an outer r housing 118 extending in a longitudinal direction for housing a medicament dose 120 in a sealed dose chamber 122 that may e an ated mouthpiece 124. In one embodiment, when the outer tubular housings 108, 118 of the reusable portion 102 and the able portion 104 are coupled together, the inhaler may have dimensions comparable to an electronic cigarette (5-15 mm in diameter and 80-150 mm in length). In another embodiment, the outer r housing can be a single tube housing both the reusable portion 102 and a disposable portion 104 and the entire inhaler can be disposable. It should be appreciated that the size and shape of inhaler housing 100 may vary to accommodate various aforementioned components.

In one embodiment, with respect to connection point 106, a user interface 116 (e.g.

LED) may be arranged as an endcap of a distal end of the outer r housing 108 of the reusable portion 102. The user interface 116 may be electronically connected to the battery 114 via controller 112 of the inhaler 100. In some embodiments, user interface 116 may e an indication that proper function of the inhaler has occurred as will be described in r detail below. In another embodiment, with respect to connection point 106, transducer 110 may be arranged as the endcap of the proximal end of the outer tubular housing 108 of the reusable portion 102. Transducer 110 may also be electronically connected to the battery 114 controller 112 of the inhaler. In some embodiment, as will be described in r detail below. A conductive spring 126 and the controller 112 may be arranged n transducer 110 and battery 114 to ensure a secure electrical and physical tion n various aforementioned components.

In some embodiments, with respect to connection point 106, the medicament dose 120 and dose chamber 122 may be arranged at the proximal end of the outer tubular housing 118 of the disposable portion 104 such that when the reusable portion 102 and a disposable portion 104 are coupled together ucer 100 may vibrate to aerosolize and transfer the medicament dose 120 into the dosing chamber 122. In some embodiments, with respect to connection point 106, mouthpiece 124 is located at the distal end of the outer tubular housing 118 of the disposable portion 104 such that the user may receive delivery of the pharmaceutical or drug from the synthetic jetting provided by transducer 100 and dosing chamber 122. In some ments, a thin membrane may be sealed to the bottom of the dose chamber 122 to ensure a secure connection to transducer 100 when the reusable n 102 and the disposable portion 104 are coupled together. In some ments, an air ?ow conduit 128 may be arranged between the dosing chamber 122 and mouthpiece 124 and con?gured to allow air to travel through the inhaler 100 when a user inhales through a mouthpiece 124.

With respect to FIGS. 2A and B, the coupling and initiation of operation of inhaler 100 is illustrated. As shown in , inhaler 100 may include a reusable n 102 and a disposable portion 104, which may be coupled together at a connection point 106 or by other convenience such as a snug-?t, detent, clamp and/or clasp. For example, disposable portion 104 may include one or more guides 140 which ?t into slots 142 of reusable portion 102 which may be secured via a twisting motion. In some embodiments, conductive spring 126 may provide resistance during the coupling of reusable portion 102 and a disposable portion 104 to provide a secure connection. With reference to , after coupling of the reusable portion 102 and the disposable n 104 is complete, the user may pull on tabs 144 to remove a seal 146 to expose the dose chamber 122 during a ?rst use. For example, tabs 144 may be ted to the seal 146 located at the te end of disposable portion 104 by one or more longitudinal members con?gured to assist in removal of the seal from the dosing chamber 122. After removal of the seal 146 of the dosing chamber 122, the user may then bring the iece 124 to their lips and start to breathe normally. During this time, the r may sense the user’s e and synchronize delivery of the pharmaceutical or drug to the user utilizing synthetic jetting as described in greater detail below. Other embodiments may use a rubber plug to seal the dose chamber or mechanisms to uncover the holes in the dose r. ion of an Inhalation Device In one embodiment rated in FIGS. 3A and B, the inhaler 100 may be con?gured to activate transducer 110 to deliver a complete medicament dose 120 to a user via synthetic jetting. During operation, when the user s through the mouthpiece 124, air is drawn into the inhaler's air ?ow conduit 128 via air vents 160, and out of the mouthpiece 124 into the user's lungs; as air is being inhaled through the air ?ow conduit 128, dry powder medicament is expelled into the air ?ow conduit 128 and becomes ned in the user's inhaled air, Thus, the air ?ow conduit 128 ably de?nes an air path from the air vents 160 to the outlet (i.e., the opening that is formed by the mouthpiece). Each breath cycle includes an inhalation and an tion, i.e., each inhalation is followed by an exhalation, so consecutive inhalations preferably refer to the inhalations in consecutive breath cycles. After each inhalation, the user may exhale outside of the inhaler (e.g., by removing his or her mouth from the mouthpiece and expelling the inhaled air off to the side). In one embodiment, consecutive inhalations refer to each time a user inhales through the r which may or may not be each time a patient inhales their breath.

In one embodiment, the inhaler 100 may contain a single pre-metered dose 120 of a dry powder drug composition comprising at least one medicament. As used herein, the pre- metered dose 120 may include a ner that is suitable for containing a dose of dry powder medicament. According to a preferred embodiment, the pre-metered dose 120 may be arranged within the disposable portion 104 of inhaler 100, which comprises a base sheet in which pre-metered dose 120 is formed to de?ne pockets n for containing distinct medicament doses and a dose chamber 122 which is sealed in such a manner that the seal 146 of the dose chamber 122 can be peeled there by providing access to the medicament of the pre-metered dose 120.

In some embodiments, inhaler 100 may be con?gured to activate the transducer 110 one or more times to deliver a complete pharmaceutical dose from a dose pellet 120 and dose chamber 122 to a user. In one embodiment, the inhaler 100 may e an air ?ow conduit 128 con?gured to allow air to travel through the inhaler 100 when a user inhales through a mouthpiece 124. For e, the controller 114 may be con?gured to activate a transducer 102 when an activation event is detected. In some embodiments, the activation event may be the removal of the seal 146 from the dose r 122. In other embodiments, the inhaler 100 may include an inhalation sensor con?gured to detect air?ow through the air ?ow conduit 124 and the activation event may be detection of an inhalation of the user. In another embodiment, the activation event may be a user inputted signal such as a push button located on the housing of the inhaler 100. The transducer 110 may be con?gured to e, thereby vibrating the pharmaceutical, to aerosolize and transfer the pharmaceutical from the dose 120 into the dosing chamber 122. In one embodiment, the vibration of the transducer 102 also delivers the aerosolized pharmaceutical into the dosing chamber 118, through the air ?ow conduit 128, and to the user h mouthpiece 124. It should be appreciated that the delivery of the pharmaceutical to the user is accomplished via synthetic jetting.

The ucer 110 may be a piezoelectric element made of a material that has a high- ncy, and preferably, ultrasonic resonant vibratory frequency (eg, about 15 to 50 kHz), and is caused to vibrate with a particular frequency and amplitude depending upon the frequency and/or amplitude of excitation icity applied to the piezoelectric element.

Examples of materials that can be used to comprise the piezoelectric element may e quartz and polycrystalline ceramic materials (e.g., barium titanate and lead zirconate titanate).

Advantageously, by vibrating the piezoelectric element at ultrasonic ncies, the noise associated with vibrating the piezoelectric element at lower (i.e., non-ultrasonic) frequencies can be avoided.

In some embodiments, the inhaler 100 may comprise an tion sensor that senses when a patient inhales through the device; for example, the sensor may be in the form of a pressure sensor, air stream velocity sensor or temperature sensor. According to one embodiment, an onic signal may be transmitting to controller 112 contained in inhaler 100 each time the sensor detects an inhalation by a user such that the dose is delivered over l inhalations by the user. For example, the sensor may comprise a conventional ?ow sensor which generates electronic signals indicative of the ?ow and/or pressure of the air stream in the air ?ow t 128, and transmits those signals via electrical tion to controller 112 contained in r 100 for controlling actuation of the transducer 110 based upon those signals. Preferably, sensor may be a pressure sensor. Non-limiting examples of pressure sensors that may be used in accordance with embodiments may include a microelectromechanical system (MEMS) pressure sensor or a nanoelectromechanical system (NEMS) pressure sensor herein. The inhalation sensor may be located in or near an air ?ow conduit 128 to detect when a user is inhaling through the mouthpiece 124.

Preferably, the controller 112 may be embodied as an application speci?c integrated circuit chip and/or some other type of very highly integrated circuit chip. Alternatively, controller 112 may take the form of a rocessor, or discrete electrical and electronic ents. As will be described more fully below, the controller 112 may control the power ed from conventional power source 114 (e.g., a DC. battery) to the transducer 110. The power may be supplied to the transducer 110 via electrical tion between the transducer 110 and the controller 112.

The memory may include non-transitory e media that electronically stores information. The memory may include one or more of optically readable storage media (e g., optical disks, etc), magnetically le e media (e.g., magnetic tape, magnetic hard drive, ?oppy drive, etc), electrical charge-based storage media (e.g., EEPROM, RAM, etc), solid-state storage media (e. g., ?ash drive, etc), and/or other electronically readable storage media. The electronic storage may store dosing technique, information determined by the sors, information received from sensor, or other information that enables the functionality as described herein.

During operation, controller 112 may also indicate proper function of inhaler 100 via user interface 116. For example, controller 112 may illuminate an LED 116 located at the end of inhaler 100 after delivery of the dose of the pharmaceutical or drug through the inhaler.

Exemplary Flowcharts illustrates a ?owchart of an exemplary method 400 of delivering a dose of a drug with an inhaler, in accordance with one or more embodiments.

In an operation 402, a reusable n and a disposable portion of an inhaler may be coupled together. In some embodiments, the reusable portion and the disposable portion may be coupled together at a connection point or by other ience such as a snug-?t, detent, clamp and/or clasp. In some embodiments, the reusable portion may include an outer tubular housing extending in a longitudinal direction for housing a transducer, controller, battery and user interface. In some embodiments, the disposable n may also include an outer r housing extending in a longitudinal direction for housing a medicament dose in a sealed dose r that may include an integrated mouthpiece.

In an operation 404, an activation event may be ed. In some embodiments, the activation event may be the removal of a seal from a dose chamber of the inhaler. In other embodiments, the activation event may be detection of an inhalation of the user. In other 10lO embodiments, the activation event may be a user inputted signal such as a push button located on the housing of the r.

In an ion 406, a transducer located within the reusable portion of the inhaler may be activated in response to detection of the activation event. In some embodiment, the ucer may be red to aerosolize the medicament when the transducer is activated.

The transducer may be a piezoelectric element made of a material that has a high-frequency, and preferably, ultrasonic resonant vibratory frequency (e.g., about 15 to 50 kHz), and is caused to vibrate with a particular frequency and amplitude depending upon the frequency and/or amplitude of excitation electricity applied to the lectric element.

In an operation 408, a pharmaceutical or drug located within the disposable n of the inhaler may aerosolize via vibrations from the transducer. In some embodiment, the medicament dose may be a single pro-metered dose pellet of a dry powder drug composition comprising at least one medicament. The pellet may be formed by compressing a dry powder drug composition. As used herein, the pre-metered dose pellet may e a ner that is suitable for containing a dose of dry powder medicament. In some embodiment, the dose pellet may be arranged within the disposable portion of inhaler, which comprises a base sheet in which pre-metered dose pellet is formed to de?ne s therein for containing distinct medicament doses and a dose chamber which is sealed in such a manner that the seal of the dose chamber can be peeled there by providing access to the medicament of the pre- metered dose pellet.

In an operation 410, the aerosolized pharmaceutical or drug may be delivered to the user through a dosing chamber and mouthpiece located within the disposable portion of the inhaler. In some embodiment, inhaler may be con?gured to activate the ucer one or more times to deliver a te pharmaceutical dose from a dose pellet and dose r to a us er.

Although the present embodiments have been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred embodiments, it is to be understood that such detail is solely for that purpose and that the embodiments are not limited to the disclosed preferred features, but, on the contrary, is intended to cover modifications and equivalent arrangements that are within the scope of the appended claims. For example, it is to be tood that the features disclosed herein contemplate that, to the extent possible, one or more es of any embodiment can be combined with one or more features of any other embodiment.

I/WE

Claims (16)

CLAIM

1. A dry powder inhaler, the dry powder inhaler sing: a disposable portion, the disposable portion including: a single pre-metered dose of a dry powder medicament; a dosing chamber configured to e the medicament; a mouthpiece configured to r the medicament in aerosolized form to the user; a reusable portion, the reusable portion ing: a transducer configured to aerosolize the medicament when the transducer is activated; and a controller configured to activate the transducer in response to an activation event; wherein the disposable portion and the reusable portion may be coupled together at a connection point; and wherein the inhaler is configured to deliver the medicament to a user via synthetic jetting.

2. The inhaler of claim 1, wherein the disposable portion and the reusable portion include outer r housings extending in a longitudinal direction.

3. The inhaler of claim 2, wherein the inhaler is about 5-15 eters in diameter and about 80-150 millimeters in length when the able portion and the reusable portion are coupled together.

4. The inhaler of claim 1, wherein the transducer is a ured to vibrate to aerosolize and transfer medicament into the dosing chamber.

5. The inhaler of claim 4, wherein aerosolized medicament is expelled into an air flow conduit of the disposable portion and is entrained in the user's inhaled air.

6. The r of claim 1, wherein the activation event includes at least one of removal of a seal from the dosing chamber, detection of a user inhalation, or a manual input by a user.

7. The inhaler of claim 1, wherein the reusable portion further includes a user interface indicating proper function of the inhaler during use.

8. The inhaler of claim 1, the dose chamber is designed in such a manner that it is unsealed there by providing access to the medicament of the pre-metered dose.

9. A dry powder inhaler for use in a method for delivering a dose of a dry powder medicament, the method comprising: coupling a disposable portion and a reusable portion of the inhaler; providing a single tered dose of a dry powder medicament located in the disposable portion of the inhaler; aerosolizing the dry powder medicament via a ucer in the reusable n of the inhaler; wherein the transducer is activated in se to an activation event via controller in the reusable portion of the r; ing an aerosolized form of the dry powder in a dosing r within the disposable portion of the inhaler; delivering the aerosolized dry powder through a mouthpiece of the disposable portion of the inhaler; wherein the inhaler delivers the dry powder medicament via tic jetting.

10. The dry powder inhaler of claim 9, wherein the disposable portion and the reusable portion include outer tubular housings extending in a longitudinal direction.

11. The dry powder inhaler of claim 10, n the inhaler is about 5-15 millimeters in diameter and about 80-150 millimeters in length when the disposable portion and the reusable portion are coupled together.

12. The dry powder inhaler of claim 9, wherein the transducer is configured to vibrate to aerosolize and transfer medicament into the dosing chamber.

13. The dry powder inhaler of claim 12, wherein lized medicament is expelled into an air flow conduit of the disposable portion and is entrained in the user's inhaled air.

14. The dry powder inhaler of claim 9, wherein the activation event includes at least one of removal of a seal from the dosing chamber, detection of a user inhalation, or a manual input by a user.

15. The dry powder inhaler of claim 9, further including: indicting proper function of the r during use via a user interface within the reusable portion of the inhaler.

16. The dry powder inhaler of claim 9, wherein the dose chamber is designed in such a manner that it is unsealed thereby providing access to the medicament of the pre-metered dose. MicroDose Therapeutx, Inc. By the Attorneys for the Applicant SPRUSON & FERGUSON Per: 124 122106 “9 “2 125 1‘14 116 FEG. 2A M...all.|!ll:lial.!!ll\n FEG. 28 7{3WW ......“WW“ A reusebie portion and e dispoeebie portion of an inhaler may be eeupied legether An ectivetieh event may be detected 406 A transducer d within the reusable portien of the inhaler may be activated in se te detection 0'? the ectivetien event .. A pharmaceutical or drug leceted Within the diepeeebie portion of the inhaler may eereeoiize via vibratiehe from the transducer The eereseiized phermaeeutieei or drug may be delivered to the user h a dosing chamber end mouthpiece located within the disposable pertien of the inheier EEG. 4